A blanket protocol to study oral regorafenib in patients with refractory liposarcoma, osteogenic sarcoma, and Ewing/Ewin

Administered By

Duke Cancer Institute

Contributors

Riedel, Richard Francis Principal Investigator

Start/End

February 1, 2014 - December 16, 2020